Prescription patterns in patients with schizophrenia in Japan: First‐quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project

Abstract Background Guideline for Pharmacological Therapy for Schizophrenia was published by the Japanese Society of Neuropsychopharmacology in 2015. "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project aimed to standardize medical practic...

Full description

Saved in:
Bibliographic Details
Main Authors: Kayo Ichihashi (Author), Hikaru Hori (Author), Naomi Hasegawa (Author), Yuka Yasuda (Author), Tomoya Yamamoto (Author), Takashi Tsuboi (Author), Kunihiro Iwamoto (Author), Taishiro Kishimoto (Author), Tadasu Horai (Author), Hiroki Yamada (Author), Nobuhiro Sugiyama (Author), Toshinori Nakamura (Author), Naohisa Tsujino (Author), Kiyotaka Nemoto (Author), Satoru Oishi (Author), Masahide Usami (Author), Eiichi Katsumoto (Author), Hidenaga Yamamori (Author), Hiroaki Tomita (Author), Taro Suwa (Author), Ryuji Furihata (Author), Takahiko Inagaki (Author), Junichi Fujita (Author), Toshiaki Onitsuka (Author), Kenichiro Miura (Author), Junya Matsumoto (Author), Kazutaka Ohi (Author), Yuki Matsui (Author), Yoshikazu Takaesu (Author), Naoki Hashimoto (Author), Junichi Iga (Author), Kazuyoshi Ogasawara (Author), Hisashi Yamada (Author), Koichiro Watanabe (Author), Ken Inada (Author), Ryota Hashimoto (Author)
Format: Book
Published: Wiley, 2020-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_3336c28c1c5847f78bd5f90f46bc9a25
042 |a dc 
100 1 0 |a Kayo Ichihashi  |e author 
700 1 0 |a Hikaru Hori  |e author 
700 1 0 |a Naomi Hasegawa  |e author 
700 1 0 |a Yuka Yasuda  |e author 
700 1 0 |a Tomoya Yamamoto  |e author 
700 1 0 |a Takashi Tsuboi  |e author 
700 1 0 |a Kunihiro Iwamoto  |e author 
700 1 0 |a Taishiro Kishimoto  |e author 
700 1 0 |a Tadasu Horai  |e author 
700 1 0 |a Hiroki Yamada  |e author 
700 1 0 |a Nobuhiro Sugiyama  |e author 
700 1 0 |a Toshinori Nakamura  |e author 
700 1 0 |a Naohisa Tsujino  |e author 
700 1 0 |a Kiyotaka Nemoto  |e author 
700 1 0 |a Satoru Oishi  |e author 
700 1 0 |a Masahide Usami  |e author 
700 1 0 |a Eiichi Katsumoto  |e author 
700 1 0 |a Hidenaga Yamamori  |e author 
700 1 0 |a Hiroaki Tomita  |e author 
700 1 0 |a Taro Suwa  |e author 
700 1 0 |a Ryuji Furihata  |e author 
700 1 0 |a Takahiko Inagaki  |e author 
700 1 0 |a Junichi Fujita  |e author 
700 1 0 |a Toshiaki Onitsuka  |e author 
700 1 0 |a Kenichiro Miura  |e author 
700 1 0 |a Junya Matsumoto  |e author 
700 1 0 |a Kazutaka Ohi  |e author 
700 1 0 |a Yuki Matsui  |e author 
700 1 0 |a Yoshikazu Takaesu  |e author 
700 1 0 |a Naoki Hashimoto  |e author 
700 1 0 |a Junichi Iga  |e author 
700 1 0 |a Kazuyoshi Ogasawara  |e author 
700 1 0 |a Hisashi Yamada  |e author 
700 1 0 |a Koichiro Watanabe  |e author 
700 1 0 |a Ken Inada  |e author 
700 1 0 |a Ryota Hashimoto  |e author 
245 0 0 |a Prescription patterns in patients with schizophrenia in Japan: First‐quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project 
260 |b Wiley,   |c 2020-09-01T00:00:00Z. 
500 |a 2574-173X 
500 |a 10.1002/npr2.12122 
520 |a Abstract Background Guideline for Pharmacological Therapy for Schizophrenia was published by the Japanese Society of Neuropsychopharmacology in 2015. "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project aimed to standardize medical practice using quality indicators (QIs) as indices to evaluate the quality of medical practice. In this study, we have reported the quality indicator values of prescription before the beginning of the guideline lectures in the EGUIDE project to ascertain the baseline status of treating patients with schizophrenia. Methods A cross‐sectional, retrospective case record survey was conducted, involving 1164 patients with schizophrenia at the time of discharge. We checked all types and dosage of psychotropic drugs. Results Forty‐three percent of patients had antipsychotic polypharmacy, and substantial concomitant medication was observed (antidepressants; 8%, mood stabilizers: 37%, anxiolytics or hypnotics: 68%). Conclusions In the results obtained in this study, we plant to report changes in the effectiveness of education in the EGUIDE project near the future. 
546 |a EN 
690 |a antipsychotics 
690 |a EGUIDE project 
690 |a guideline 
690 |a quality indicator 
690 |a schizophrenia 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Neurosciences. Biological psychiatry. Neuropsychiatry 
690 |a RC321-571 
655 7 |a article  |2 local 
786 0 |n Neuropsychopharmacology Reports, Vol 40, Iss 3, Pp 281-286 (2020) 
787 0 |n https://doi.org/10.1002/npr2.12122 
787 0 |n https://doaj.org/toc/2574-173X 
856 4 1 |u https://doaj.org/article/3336c28c1c5847f78bd5f90f46bc9a25  |z Connect to this object online.